Board of Directors   Print Screen
 

QuantRx® Directors & Executive Officers
Walter W. Witoshkin, Director, Chairman & Chief Executive Officer
William H. Fleming, Ph.D., Director, Secretary, Chief Scientific Officer & President of Diagnostics
Shalom Hirschman, M.D., Director
Patrick T. Mooney, M.D., Director

Robert G. Pinco, Director

Walter W. Witoshkin is Chairman and Chief Executive Officer of QuantRx Biomedical Corporation. A 40-year veteran of the pharmaceutical, healthcare, and biomedical industries, Mr. Witoshkin joined QuantRx in 2005. He has held senior executive positions at leading healthcare product and pharmaceutical companies, most recently SmithKline Beecham, now GlaxoSmithKline, where he was Vice President of Business Development and Chief Financial Officer. In 1989, Mr. Witoshkin established Menley & James Laboratories, Inc., after purchasing 32 SmithKline Beecham over-the-counter pharmaceutical and toiletry product brands. Menley & James had its initial public offering in 1992. He earlier held several senior finance positions at American Cyanamid, which became American Home and then Wyeth. Mr. Witoshkin joined QuantRx from Trident Group LLC; global operational consultants to the pharmaceutical and related healthcare industries. As a founding partner of Trident Group, Mr. Witoshkin specialized in alternative sourcing for manufacturing and the acquisition of technologies and products.

William H. Fleming, Ph.D. was named Chief Scientific Officer of QuantRx in July 2005. He also serves as a Director and the Secretary of the company; a position he has held since 1994. He was the Company’s Vice President of Diagnostics from 1997 through July 2005 and Acting CEO from 2003 until May 2005. He was President and Chief Operating Officer from 1994 to 1997. Dr. Fleming was President, Chief Operating Officer and a Director of ProFem until its merger with QuantRx in June 1994. Dr. Fleming was also affiliated with Sovereign Ventures, a healthcare consulting firm, and concurrently served as Director of Corporate Development of Antivirals, Inc., a biotechnology company involved in antisense technology. Dr. Fleming is a Director of ERC, a non-profit company.

Shalom Hirschman, M.D. has served as a Director of QuantRx since September 2005. Dr. Hirschman was Professor of Medicine, Director of the Division of Infectious Diseases and Vice Chairman of the Department of Medicine at Mt. Sinai School of Medicine and the Mount Sinai Hospital. He served nearly three decades at Mt. Sinai until his retirement, when he became CEO, President, and Chief Scientific Officer of Advanced Viral Research Corporation, from which he retired in 2004.

Patrick T. Mooney, M.D. has served as a Director of QuantRx since May 2010.  Dr. Mooney joined Echo Therapeutics, Inc. as its Chief Executive Officer in September 2007 and as its President in June 2009. In January 2008, Dr. Mooney was appointed Chairman of the Board of Directors. Dr. Mooney previously served as President, Chief Executive Officer and Director of Echo Therapeutics, Inc. (a privately-held company prior to its merger with Sontra Medical Corporation) from September 2006 to September 2007. Prior to joining Echo Therapeutics, Inc., Dr. Mooney was President, Chief Executive Officer and Chairman of Aphton Corporation, a biopharmaceutical company, from January 2004 to November 2006. Dr. Mooney served as Senior Biotechnology Analyst at Thomas Weisel Partners, LLC, a full service merchant banking firm, and as Senior Biotechnology Analyst at Janney Montgomery Scott, LLC, a full services investment banking firm.

Robert G. Pinco has served as a Director of QuantRx since May 2010.  As Senior Counsel for Buchanan Ingersoll & Rooney PC, Mr. Pinco represents worldwide brand-name and prominent technology companies. He previously served as Head of the  Firm's Food & Drug Administrative Law Group and as Co-Chairman of the Worldwide Biotechnology Group. He counsels clients on regulatory matters, including the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) issues. Mr. Pinco also focuses on combining his FDA knowledge with the corporate securities, intellectual property and venture capital capabilities of Buchanan Ingersoll & Rooney to assist in the creation and development of pharmaceutical and medical device companies in the U.S., Europe and the Pacific Rim. His previous experience at the White House, the Drug Enforcement Administration (DEA), the FDA, the U.S. Attorney's Office and as a pharmacist has enabled him to develop knowledge in marketing over-the-counter (OTC) drugs without FDA preclearance, modification of drug standards, avoiding long drug preclearance delays, switching drugs from prescription to OTC status and handling high-tech drug development problems.

 
 

© Copyright 2007 - QuantRx® Biomedical Corporation